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Summary The beneﬁcial effects of -blocker therapy on the clinical outcomes of heart failure
with reduced ejection fraction (HFREF) are attributed to the improvement in ejection fraction
(EF) and left ventricular (LV) reverse remodeling. Previous studies only reported the -blocker
therapy-induced improvement of diastolic function accompanied by the increase in EF in HFREF
patients. This retrospective study aimed to elucidate whether -blocker therapy improves dias-
tolic function even without an increase in EF. Out of the consecutive 11,830 echocardiographic
reports, HFREF patients without an increase in EF following long-term -blocker therapy com-
prised the study subjects (n = 19). During the mean follow-up of 17 months, -blocker therapy
signiﬁcantly decreased peak mitral E-wave velocity (70± 25—50± 18 cm/s, p < 0.01) and ratio of
peak mitral E- to A-wave velocities (E/A ratio) (1.4± 0.8—0.9± 0.4, p < 0.05), prolonged decel-
eration time of the mitral E-wave velocity (DcT) (167± 54—206± 61ms, p < 0.05), and improved
New York Heart Association functional class (2.3± 0.7—1.8± 0.4, p < 0.01) without changes in
LV volume. Because DcT and E/A ratio are well known to correlate with LV ﬁlling pressures in
patients with reduced EF, our results indicate a reduction in LV ﬁlling pressures without changes
in LV volume, suggesting a reduction in LV stiffness. Thus, long-term -blocker therapy is likely
∗ Corresponding author. Tel.: +81 6 6879 6612; fax: +81 6 6879 6613.
E-mail address: kazuhiro@medone.med.osaka-u.ac.jp (K. Yamamoto).
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to improve diastolic function even without a concomitant increase in EF in HFREF patients, which
may be also responsible for the -blocker-induced improvement of their symptoms of heart
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To evaluate the relation between the patients’ baseline
characteristics and the -blocker-induced changes in the
parameters of the transmitral ﬂow velocity curves (mitral E-failure.
© 2010 Japanese College of C
Introduction
In the last decade, clinical evidence has accumulated to
indicate the beneﬁcial effects of -blockers on clinical
outcomes in heart failure with reduced ejection fraction
(HFREF) [1—4]. The beneﬁcial effects are attributed to
an improvement in ejection fraction (EF) and the reduc-
tion of left ventricular (LV) volume [5—11], and HFREF
patients without an improvement in EF following long-term
-blocker therapy are considered as non-responders to
-blocker therapy.
It has been revealed that diastolic function is an inde-
pendent determinant of the symptoms and the prognosis
of HFREF patients [12—14]. Previous studies have demon-
strated that -blocker therapy improves LV diastolic function
in association with the increase in EF [15—19]; however,
it remains unclear whether an improvement in LV diastolic
function can be expected even in HFREF patients without
the desirable response in EF to long-term -blocker ther-
apy. If LV diastolic function is improved even without the
therapeutic effects on EF, the HFREF patients without the -
blocker therapy-induced increase in EF may not necessarily
be non-responders to this therapy.
This study aimed to elucidate whether long-term -
blocker therapy improves diastolic function in HFREF
patients even without a signiﬁcant increase in EF.
Patients and methods
Patients
This retrospective study was approved by Osaka University
Hospital Ethical Committee. Among the consecutive 11,830
records of echocardiography in our hospital between Jan-
uary 2005 and October 2009, 827 patients with LVEF 40%
were identiﬁed. Out of these 827 patients, HFREF patients
who met the following criteria in our outpatient clinic were
enrolled in this study; LVEF was 40% before the initia-
tion of -blocker therapy, heart failure was diagnosed and
-blocker therapy was initiated in our hospital, echocardio-
graphic data were obtained before and more than 6 months
after the initiation of -blocker. Patients were excluded
if they had a relative increase in LVEF 25% versus base-
line after the treatment with -blocker, severe valvular
heart disease, congenital heart disease, renal failure (serum
creatinine level >2.0mg/dl), atrial ﬁbrillation, myocar-
dial infarction and/or coronary revascularization within 6
months of the initiation of -blocker, permanent pacemak-
ers and/or deﬁbrillators. This cutoff value is >2 SD above the
changes in LVEF observed after administration of placebo in
randomized trials with ß-blockers, and has been used in pre-
vious studies to assess the therapeutic effects in patients
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ith reduced LVEF [20]. The patients with a history of left
entriculoplasty or of LV assist device implantation were
lso excluded. Finally, 19 patients met the criteria, and
heir data before the initiation of -blocker therapy were
ompared to those more than 6 months after the initia-
ion. An improvement in New York Heart Association (NYHA)
unctional class 1 following -blocker therapy was deﬁned
s the improvement in symptoms of heart failure in this
tudy.
chocardiography
V dimensions were measured from M-mode echocardiog-
aphy in the parasternal long-axis view. LV end-diastolic
imension (LVEDD) was measured at the onset of the QRS
omplex on the electrocardiogram, and LV end-systolic
imension (LVESD) was deﬁned by the smallest LV cavity. Left
trial dimension (LAD) was measured as the distance from
he leading edge of the posterior aortic wall to the lead-
ng edge of the posterior left atrial wall at end-systole. The
itral ﬂow velocity was recorded in the apical 4-chamber
iew by placing the sample volume of the pulsed wave
oppler echocardiography at the mitral valve tip, and peak
arly (E) and late (A) transmitral ﬂow velocities were mea-
ured. The deceleration time of the mitral E-wave (DcT) was
easured from its peak to the time when the descent of the
ave intercepted the baseline [21—23]. LV end-systolic and
nd-diastolic volumes were measured with biplane Simp-
ons’ method to calculate EF and were corrected for body
urface area to calculate LV end-systolic (LVESVI) and end-
iastolic volume index (LVEDVI).
tatistical analysis
ll statistical analyses were performed using the Stat-View
tatistical package, version 5.0 (SAS Institute Inc., Cary, NC,
SA). Numeric results are expressed as the mean± SD. The
ifferences of continuous variables, NYHA functional class
nd mitral regurgitation (MR) grade before and after the
nitiation of -blocker were evaluated using the Wilcoxon
igned-rank test, and the differences in the changes in the
arameters of the transmitral ﬂow velocity curves between
wo groups were evaluated using the Mann—Whitney U
est. Correlations among the changes in various variables
ere evaluated with Spearman’s correlation coefﬁcient.ave velocity, E/A ratio, and DcT), the study patients were
ivided into two groups by the mean value of each continu-
us variable of baseline characteristics. For NYHA class, the
atients were divided into those with NYHA class I or II and
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Table 1 Clinical and study characteristics in the study
patients.
Age (years) 57± 14
Gender (male) 84%
Ischemic heart disease 47%
Medications
ACE inhibitors 63%
Angiotensin II receptor antagonists 32%
Diuretics 74%
Statins 53%
Digitalis 16%
Calcium channel blockers 21%
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DiscussionSerum creatinine level (mg/dl) 1.0± 0.3
ACE: angiotensin-converting enzyme.
ith NYHA class III or IV. A p-value <0.05 was considered
tatistically signiﬁcant.
esults
atients’ characteristics before the initiation of -blocker
re summarized in Table 1. The mean patient age was 57
ears, and 84% of the patients were men. The underlying
isease was ischemic heart disease in 9 patients and idio-
athic dilated cardiomyopathy in 10 patients. In all of the
tudy subjects, carvedilol was prescribed for HFREF, and the
ean total daily dose of carvedilol was 16± 9mg. The mean
ollow-up period was 17± 11 months.
The -blocker therapy did not change blood pressure,
V volumes, EF, MR grade, and LAD except heart rate
n the subjects of this study. In contrast, the adminis-
ration of -blocker signiﬁcantly decreased mitral E-wave
T
c
u
Table 2 Clinical and study characteristics at entry and follow-up
Entry
Heart rate (beats/min) 77 ± 10
Systolic blood pressure (mmHg) 116 ± 17
Diastolic blood pressure (mmHg) 65 ± 13
Echocardiography
LVEDVI (ml/m2) 123 ± 33
LVESVI (ml/m2) 84 ± 30
LVEDD (mm) 65 ± 7
LVESD (mm) 55 ± 7
LVEF (%) 34 ± 6
MR grade 2.1 ± 0.9
LAD (mm) 44 ± 6
Mitral E-wave velocity (cm/s) 70 ± 25
Mitral A-wave velocity (cm/s) 58 ± 19
E/A ratio 1.4 ± 0.8
DcT (ms) 167 ± 54
NYHA functional class 2.3 ± 0.7
DcT, deceleration time of mitral E-wave velocity; E/A ratio, ratio of p
left atrial dimension; LVEDD, left ventricular end-diastolic dimension
ventricular ejection fraction; LVESD, left ventricular end-systolic dim
mitral regurgitation; NYHA, New York Heart Association.S. Tamaki et al.
elocity and E/A ratio, and increased DcT. In associa-
ion with these changes in the indices of the transmitral
ow velocity curves, NYHA class signiﬁcantly improved
Table 2). Correlation analysis revealed that there was
o signiﬁcant association between the change in heart
ate and the changes in any indices of the transmitral
ow velocity curves. In particular, the -blocker-induced
hanges in mitral E-wave velocity, E/A ratio, and DcT
ere remarkable in the patients with an improvement of
YHA class  1 compared to the other patients. Heart
ate was decreased in both the patients with and with-
ut an improvement of NYHA class (Table 3). In either
atient group, there was no signiﬁcant change in LV volume
r EF.
The changes in mitral E-wave velocity and E/A ratio were
igniﬁcantly greater in the patients with high baseline mitral
-wave velocity or in those with high baseline E/A ratio
han in those with low baseline values. The patients with
ow baseline mitral A-wave velocity showed a signiﬁcantly
reater change in E/A ratio than those with high values.
/A ratio decreased more in the patients treated without
ngiotensin II receptor antagonists than in those with them,
nd DcT was more prolonged in the patients treated with
tatins than in those without them. Additionally, the change
n E/A ratio was signiﬁcantly greater in the patients with
igh baseline heart rate than in the other group (Table 4).
here was no other association between the patients’ base-
ine characteristics and the changes in the transmitral ﬂow
elocity curves.o address the issue whether -blockers provide beneﬁ-
ial effects on LV diastolic function in HFREF patients even
nassociated with an improvement in EF, we enrolled the
period in the study patients.
Follow-up p-value
67 ± 9 0.0008
115 ± 18 NS
67 ± 7 NS
112 ± 28 NS
74 ± 26 NS
61 ± 8 NS
51 ± 9 0.0289
34 ± 8 NS
1.5 ± 1.0 NS
40 ± 8 NS
50 ± 18 0.0040
60 ± 15 NS
0.9 ± 0.4 0.0269
206 ± 61 0.0298
1.8 ± 0.4 0.0067
eak mitral E-wave velocity to peak mitral A-wave velocity; LAD,
; LVEDVI, left ventricular end-diastolic volume index; LVEF, left
ension; LVESVI, left ventricular end-systolic volume index; MR,
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Table 3 The -blocker-induced changes in the indices of the transmitral ﬂow velocity curves and heart rate.
Entry Follow-up p-value
Patients with an improvement in NYHA class  1 (n = 8)
Mitral E-wave velocity (cm/s) 74 ± 29 49 ± 22 0.0207
Mitral A-wave velocity (cm/s) 51 ± 16 57 ± 7 NS
E/A ratio 1.7 ± 1.0 0.8 ± 0.4 0.0251
DcT (ms) 149 ± 50 210 ± 78 NS
Heart rate (beats/min) 78 ± 12 65 ± 7 0.0117
Patients without an improvement in NYHA class (n = 11)
Mitral E-wave velocity (cm/s) 67 ± 22 50 ± 17 NS
Mitral A-wave velocity (cm/s) 63 ± 21 62 ± 18 NS
E/A ratio 1.2 ± 0.7 0.9 ± 0.5 NS
5
of pe
vDcT (ms) 181 ± 5
Heart rate (beats/min) 77 ± 9
DcT, deceleration time of mitral E-wave velocity; E/A ratio, ratio
HFREF patients without response in EF to long-term -
blocker therapy, and evaluated the changes in the pulsed
Doppler transmitral ﬂow velocity curves which allow the
noninvasive assessment of LV diastolic function and ﬁll-
ing pressures in the presence of LV systolic dysfunction
[24,25].
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Table 4 The relation between the patients’ baseline characteris
the transmitral ﬂow velocity curves.
Change in mitral E-wave
velocity (cm/s)
Baseline mitral E-wave velocity
With high value −35± 18
With low value −5± 18
p-value 0.0042
Baseline A—–wave velocity
With high value —
With low value —
p-value NS
Baseline E/A ratio
With high value −37± 16
With low value −8± 20
p-value 0.0057
Baseline angiotensin II
receptor antagonist therapy
With therapy —
Without therapy —
p-value NS
Baseline statin therapy
With therapy —
Without therapy —
p-value NS
Baseline heart rate
With high value —
With low value —
p-value NS
DcT, deceleration time of mitral E-wave velocity; E/A ratio, ratio of pe202 ± 50 NS
69 ± 10 0.0327
ak mitral E-wave velocity to peak mitral A-wave velocity.
The current study demonstrated that mitral E-wave
elocity and E/A ratio signiﬁcantly decreased with the pro-
ongation of DcT following long-term -blocker therapy
ithout signiﬁcant changes in LVEDVI in HFREF patients with-
ut a responsive increase in EF. Previous clinical studies
howed that both the decrease in mitral E-wave velocity
tics and the -blocker-induced changes in the parameters of
Change in E/A ratio Change in DcT (ms)
−1.1± 0.8 —
0.0± 0.5 —
0.0025 NS
0.0± 0.6 —
−0.9± 0.9 —
0.0390 NS
−1.3± 0.7 —
0.0± 0.5 —
0.0007 NS
0.1± 0.6 —
−0.8± 0.8 —
0.0437 NS
— 69± 68
— 8± 45
NS 0.0454
−0.9± 0.9 —
−0.2± 0.7 —
0.0412 NS
ak mitral E-wave velocity to peak mitral A-wave velocity.
1a
o
t
l
v
I
i
e
c
a
o
f
[
l
e
b
T
t
p
p
t
p
t
t
s
o
f
(
t
o
i
p
a
t
t
i
ﬂ
u
d
e
t
t
[
s
c
I
e
H
i
r
t
t
r
f
r
w
e
t
t
a
l
r
i
S
T
o
a
i
b
i
i
f
f
d
r
t
d
t
n
a
i
i
g
b
r
g
c
n
n
a
a
t
H
a
v
s
t
f
a
t
c
u
a
c
l
u
E
[
t
v
d
p
d
U80
nd E/A ratio and the increase in DcT indicate the reduction
f LV ﬁlling pressures in the presence of LV systolic dysfunc-
ion [24,25]. Therefore, long-term -blocker therapy was
ikely to decrease LV ﬁlling pressure without changes in LV
olume in this study, indicating the reduction of LV stiffness.
t is noted that these changes were remarkable particularly
n the patients in whom the improvement in symptoms was
vident. The beneﬁcial effects of -blocker therapy on clini-
al outcomes have been attributed to LV reverse remodeling
nd the improvement of LV systolic function [6—11]. Previ-
us studies have shown that the improvement in LV diastolic
unction is concomitant with [16,17,26] and is followed by
15,18,19] the increase in EF. This study demonstrated that
ong-term -blocker therapy improves LV diastolic function
ven without an increase in EF, which is partly compati-
le with the previous study of Paraskevaidis et al. [27].
his study expanded the previous study by demonstrating
hat the beneﬁcial effects on LV diastolic function accom-
anied the improvement of heart failure symptoms in HFREF
atients. In addition, greater -blocker-induced changes in
he transmitral ﬂow velocity curves were observed in the
atients with high baseline E-wave velocity and E/A ratio
han in those with low values, and this result may underscore
he efﬁcacy of -blocker therapy in the HFREF patients with
evere diastolic dysfunction.
The current results are partly compatible with the previ-
us experimental studies with the animal model of heart
ailure with preserved EF and LV diastolic dysfunction
HFPEF). Our and other experimental studies have shown
hat long-term -blocker therapy improves the survival rate
f the animal HFPEF model [28,29]. The previous exper-
mental and clinical studies indicated that LV stiffening
lays a crucial role in the transition to HFPEF [30,31],
nd our animal study showed that long-term -blocker
herapy attenuated LV ﬁbrosis and stiffening [29]. Thus,
he -blocker therapy-induced attenuation of LV stiffen-
ng may well explain the alterations of the transmitral
ow velocity curves without signiﬁcant changes in LV vol-
me in this study. Although this clinical study lacks the
ata about the mechanisms of the improvement of LV stiff-
ning by -blocker therapy, our animal study suggested
hat the suppression of oxidative stress and of inﬂamma-
ory changes contributes to the attenuation of LV stiffening
29].
Long-term -blocker therapy reduced heart rate in this
tudy (Table 2), and this might have provided beneﬁ-
ial effects on LV diastolic function. However, the CIBIS
I trial demonstrated that heart rate reduction cannot
xplain -blocker-induced improvement of prognosis in
FREF patients [32], and the previous experimental stud-
es have shown that heart rate reduction therapy does not
esult in an improvement in LV diastolic function or a reduc-
ion in LV ﬁlling pressures [33,34]. Moreover, a recent clinical
rial showed the failure of heart rate reduction therapy to
educe cardiovascular death and hospitalization due to heart
ailure in patients with reduced EF [35]. In this study, heart
ate was decreased to a similar degree in both the patients
ith and without an improvement in NYHA class, and the
ffects on LV diastolic function were different between the
wo groups. In addition, there was no signiﬁcant associa-
ion between the change in heart rate and the changes in
ny indices of the transmitral ﬂow velocity curves by corre-
a
o
b
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tS. Tamaki et al.
ation analysis. Thus, the effects of the reduction of heart
ate on LV diastolic function may be small in this study, even
f present.
tudy limitations
here are several limitations to this study. First, the number
f the study subjects was small. This is because -blockers
re usually initiated early after the onset of myocardial
nfarction, a small dose of -blockers had been prescribed
y other hospitals in most HFREF patients before they were
ntroduced to our hospital for the diagnosis of underly-
ng cardiovascular diseases or the stabilization of heart
ailure, and/or the long-term administration of -blockers
requently increases EF. All of the patients with these con-
itions were excluded from this study. Second, this is a
etrospective study, which resulted in substantial varia-
ion in the interval of echocardiographic studies, -blocker
osage, or the time from the initial echocardiogram until
he onset of therapy (1.7± 3.2 months). Although this may
ot affect our conclusion that long-term -blocker ther-
py improves diastolic function even without a concomitant
ncrease in EF in HFREF patients, future prospective stud-
es are required to clarify which patients are provided
reat beneﬁts by -blocker therapy or which doses of -
locker provide beneﬁcial effects on diastolic function. This
etrospective study may be affected by variability in sono-
raphers performing studies; however, our laboratory has
onﬁrmed small technical variations [22,36,37]. This study is
ot a randomized controlled prospective study, and we could
ot compare the changes between the HFREF patients with
nd without -blocker therapy; however, such a study is not
llowed for the ethical reason in this era when the -blocker
herapy has been established as effective in patients with
FREF or myocardial infarction. Third, we noninvasively
ssessed LV diastolic performance with the transmitral ﬂow
elocity curves. The previous clinical studies have demon-
trated the reliability of the transmitral ﬂow velocity curves
o assess LV ﬁlling pressures in the presence of systolic dys-
unction [24,25], and the comparison of the data before and
fter the initiation of the -blocker therapy is required in
his study. Furthermore, the changes in the ﬂow velocity
urves were related to the improvement in the heart fail-
re symptoms in this study. Thus, the lack of the invasive
ssessment of LV diastolic performance may not affect our
onclusions. Fourth, one may argue that EF will increase
ater in the subjects of this study. However, the mean follow-
p period was 17 months, and it is commonly believed that
F increases by 6 months after the initiation of -blockers
7,16]. Fifth, the assessment of the effects of -blocker
herapy on diastolic function in HFPEF patients may pro-
ide direct proof. However, the noninvasive evaluation of LV
iastolic function and/or ﬁlling pressures in subjects with
reserved EF has not been established. Sixth, the prescribed
oses of carvedilol in this study were lower than those in the
SA or European countries. This is because the maximal dose
llowed in Japan is 20mg/day. Lastly, we could obtain data
f tissue Doppler imaging of the mitral annular movement
oth before and after -blocker therapy in only 6 of the 19
ubjects. Although tissue Doppler imaging has been shown
o be useful for the estimation of LV ﬁlling pressures [38],
[[
[
[
[
[
[
[
[
[Beta-blocker improves diastolic function
we could not assess the effects of -blocker therapy on this
imaging.
Conclusion
Long-term -blocker therapy improves diastolic function
even without a concomitant increase in EF in HFREF
patients. This may at least partly contribute to the
improvement in symptoms in HFREF patients treated with
-blockers, and it is unlikely appropriate to deﬁne patients
without a responsive increase in EF as non-responders to
-blocker therapy. The current results also suggest the ben-
eﬁcial effects of -blocker therapy in HFPEF patients with
diastolic dysfunction as well as in HFREF patients, which is
currently being investigated [39].
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